Bausch Health

Brera Holdings Signs All-Star Advisory Board to Lead Soccer World’s First Nasdaq-Listed Multi-Club Ownership Model

Retrieved on: 
Tuesday, February 27, 2024

DUBLIN, Ireland and MILAN, Italy, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Brera Holdings PLC (“Brera Holdings”, “Brera” or the “Company”) (Nasdaq: BREA) is pleased to announce the formation of a top-tier Advisory Board to lead the world’s first publicly-traded multi-club ownership (“MCO”) company in global football (American soccer).

Key Points: 
  • DUBLIN, Ireland and MILAN, Italy, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Brera Holdings PLC (“Brera Holdings”, “Brera” or the “Company”) (Nasdaq: BREA) is pleased to announce the formation of a top-tier Advisory Board to lead the world’s first publicly-traded multi-club ownership (“MCO”) company in global football (American soccer).
  • Rothenberg was president of U.S. Soccer , the governing body of American soccer during the 1990s and oversaw both the 1994 FIFA World Cup in the United States and the establishment of Major League Soccer (“MLS”) in 1996.
  • Geller has been a member of the board of directors for numerous Nasdaq and New York Stock Exchange listed companies.
  • “Landing an all-star team to join our Advisory Board is a resounding stamp of approval for Brera’s business model.

TUX Creative Agency Acquires L.A.-based Another Creative

Retrieved on: 
Tuesday, February 20, 2024

LOS ANGELES, Feb. 20, 2024 /PRNewswire/ - TUX Creative is thrilled to announce the successful integration of Los Angeles-based agency Another Creative.

Key Points: 
  • LOS ANGELES, Feb. 20, 2024 /PRNewswire/ - TUX Creative is thrilled to announce the successful integration of Los Angeles-based agency Another Creative.
  • Chelsea Matthews, the visionary founder of Another Creative, will join TUX's executive team, stepping into the role of Vice President of Creative and Partner for the U.S. business.
  • The entire Another Creative team will join her at TUX.
  • Chelsea's wealth of experience and innovative perspective will contribute to shaping the creative direction of TUX going forward.

Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors

Retrieved on: 
Monday, February 5, 2024

Mr. McKenna's track record of corporate leadership, product development, and value creation, particularly in IBD.

Key Points: 
  • Mr. McKenna's track record of corporate leadership, product development, and value creation, particularly in IBD.
  • The Company looks forward to his guidance as it advances its potentially best-in-class antibodies targeting α4β7 and TL1A into clinical trials this year.
  • "Spyre had an impressive 2023, raising $390M through the capital markets with a syndicate of top-tier biotechnology investors," said Mr. McKenna.
  • In connection with Mr. McKenna's appointment to the Company's Board, Alison Lawton has resigned effective February 1, 2024.

Mallinckrodt Announces Board of Directors and Leadership Updates

Retrieved on: 
Friday, February 2, 2024

DUBLIN, Feb. 2, 2024 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced the appointments of Paul Bisaro, Katina Dorton, Abbas Hussain and Wesley Wheeler to its Board of Directors, effective immediately. Mr. Bisaro has also been reappointed to his previous role as Board Chair. In addition, the Company announced that Siggi Olafsson has entered into a new employment agreement and will continue in his roles as Mallinckrodt's President and Chief Executive Officer and a member of the Board.

Key Points: 
  • Four Directors Added to Board Bring Seasoned Experience in Pharmaceuticals, Healthcare, Finance and Operations
    Siggi Olafsson Will Continue as President, CEO and Board Member
    DUBLIN, Feb. 2, 2024 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced the appointments of Paul Bisaro, Katina Dorton, Abbas Hussain and Wesley Wheeler to its Board of Directors, effective immediately.
  • Our ability to attract these accomplished directors is a testament to what we have achieved so far and the opportunities ahead for Mallinckrodt."
  • Select professional highlights of Mallinckrodt's new directors include:
    Paul Bisaro is a healthcare industry leader with more than three decades of leadership experience at generic and branded pharmaceutical companies.
  • With the appointment of Messrs Bisaro, Hussain and Wheeler and Ms. Dorton, Mallinckrodt's Board comprises seven directors.

CORRECTION BY SOURCE: Solta Medical's Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China

Retrieved on: 
Monday, January 22, 2024

[See *Correction above: The TR-4 Return Pad is not approved for use by the U.S. Food & Drug Administration.]

Key Points: 
  • [See *Correction above: The TR-4 Return Pad is not approved for use by the U.S. Food & Drug Administration.]
  • "The approval of Thermage FLX, and the TR-4 return pad, marks a significant milestone for Solta Medical," Thomas J. Appio, Bausch Health Chief Executive Officer, said.
  • "The approval from NMPA means we are able to continue the momentum of the growth of Thermage in China," Jiny Kim, Senior Vice President, Solta Medical, said.
  • Ask your doctor for more information about Thermage FLX and see www.thermage.com for additional details.

Damola Adamolekun Joins Garnett Station Partners as Operating Partner

Retrieved on: 
Wednesday, January 17, 2024

Garnett Station Partners, LLC (“Garnett Station”), a New York-based principal investment firm that manages over $2.2 billion of assets, today announced that Damola Adamolekun has joined the firm as an Operating Partner.

Key Points: 
  • Garnett Station Partners, LLC (“Garnett Station”), a New York-based principal investment firm that manages over $2.2 billion of assets, today announced that Damola Adamolekun has joined the firm as an Operating Partner.
  • In this role, Adamolekun will help identify new investment opportunities and drive innovation, value and efficiency within Garnett Station’s portfolio of brands.
  • Adamolekun brings over a decade of investment and corporate leadership expertise, specifically in the food and beverage sectors.
  • Adamolekun added, “Matt, Alex and the entire Garnett Station team have an impressive track record of creating value and turbo-charging growth across all their brands.

miraDry® Appoints Medical Aesthetic Leaders Amber Edwards as Chair and Robert Catlin as New Chief Executive Officer

Retrieved on: 
Tuesday, January 16, 2024

NEWPORT BEACH, Calif., Jan. 16, 2024 /PRNewswire/ -- miraDry, the global medical device leader in underarm sweat and odor treatment, announces Amber Edwards as newly appointed Chair and Robert Catlin, former SVP and General Manager of Endo Aesthetics, as Chief Executive Officer. Arash Khazei will step down as Chief Executive Officer, continuing in the near term as a strategic advisor to the company. Together Ms. Edwards and Mr. Catlin bring a wealth of experience in global commercial excellence, positioning miraDry for significant expansion.

Key Points: 
  • NEWPORT BEACH, Calif., Jan. 16, 2024 /PRNewswire/ -- miraDry, the global medical device leader in underarm sweat and odor treatment, announces Amber Edwards as newly appointed Chair and Robert Catlin, former SVP and General Manager of Endo Aesthetics, as Chief Executive Officer.
  • Arash Khazei will step down as Chief Executive Officer, continuing in the near term as a strategic advisor to the company.
  • Together Ms. Edwards and Mr. Catlin bring a wealth of experience in global commercial excellence, positioning miraDry for significant expansion.
  • "We are thrilled to have Rob Catlin join this dynamic team bringing broad commercial leadership experience in dermatologic and aesthetic categories.

miraDry® Appoints Medical Aesthetic Leaders Amber Edwards as Chair and Robert Catlin as New Chief Executive Officer

Retrieved on: 
Tuesday, January 16, 2024

NEWPORT BEACH, Calif., Jan. 16, 2024 /PRNewswire/ -- miraDry, the global medical device leader in underarm sweat and odor treatment, announces Amber Edwards as newly appointed Chair and Robert Catlin, former SVP and General Manager of Endo Aesthetics, as Chief Executive Officer. Arash Khazei will step down as Chief Executive Officer, continuing in the near term as a strategic advisor to the company. Together Ms. Edwards and Mr. Catlin bring a wealth of experience in global commercial excellence, positioning miraDry for significant expansion.

Key Points: 
  • NEWPORT BEACH, Calif., Jan. 16, 2024 /PRNewswire/ -- miraDry, the global medical device leader in underarm sweat and odor treatment, announces Amber Edwards as newly appointed Chair and Robert Catlin, former SVP and General Manager of Endo Aesthetics, as Chief Executive Officer.
  • Arash Khazei will step down as Chief Executive Officer, continuing in the near term as a strategic advisor to the company.
  • Together Ms. Edwards and Mr. Catlin bring a wealth of experience in global commercial excellence, positioning miraDry for significant expansion.
  • "We are thrilled to have Rob Catlin join this dynamic team bringing broad commercial leadership experience in dermatologic and aesthetic categories.

Dana Incorporated Appoints Steven Miller to Board of Directors

Retrieved on: 
Monday, November 13, 2023

MAUMEE, Ohio, Nov. 13, 2023 /PRNewswire/ -- Dana Incorporated (NYSE: DAN) today announced that Steven Miller has been appointed to the Dana board of directors, effective Nov. 9, 2023.  Mr. Miller will replace Brett Icahn as an Icahn Capital board designee, pursuant to the January 2022 Director Appointment and Nomination Agreement between Icahn Capital and Dana.

Key Points: 
  • MAUMEE, Ohio, Nov. 13, 2023 /PRNewswire/ -- Dana Incorporated (NYSE: DAN) today announced that Steven Miller has been appointed to the Dana board of directors, effective Nov. 9, 2023.
  • Mr. Miller will replace Brett Icahn as an Icahn Capital board designee, pursuant to the January 2022 Director Appointment and Nomination Agreement between Icahn Capital and Dana.
  • "On behalf of the Dana board of directors, I want to welcome Steven as a director, and we look forward to collaborating as we continue to drive profitable growth," said James Kamsickas, Dana chairman and CEO.
  • "I am grateful for the opportunity to have served on the Dana Board and to have worked with the dedicated Dana team," said Brett Icahn.

Innovid Reports Q3 2023 Financial Results

Retrieved on: 
Wednesday, November 8, 2023

Our Q3 results are evidence of our increased operational efficiency and our focus on profitable growth.

Key Points: 
  • Our Q3 results are evidence of our increased operational efficiency and our focus on profitable growth.
  • Innovid will be hosting an Investor Day detailing the company's vision, market opportunities, and product innovation on November 30, 2023 in New York City.
  • Innovid is providing the following financial guidance for Q4 and full year 2023:
    Q4 2023 revenue in a range between $35 million and $37 million.
  • Innovid also discloses and discusses non-GAAP financial measures such as Adjusted EBITDA and Adjusted EBITDA margin and Free Cash Flow.